EMEA-002896-PIP01-20 - paediatric investigation plan

single chain urokinase plasminogen activator (scuPA)

Key facts

• Active substance:
  single chain urokinase plasminogen activator (scuPA)
• Therapeutic area:
  Pneumology-allergology
• Decision number:
  P/0391/2021
• PIP number:
  EMEA-002896-PIP01-20
• Pharmaceutical form(s):
  Powder for solution for injection
• Condition(s) / indication(s):
  Treatment of pleural effusion
• Route(s) of administration:
  Intrapleural use
• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  08/09/2021
• Compliance check done:
  No

Decision

P/0391/2021 : EMA decision of 8 September 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for single chain urokinase plasminogen activator (scuPA) (EMEA-002896-PIP01-20)

Adopted Reference Number: EMA/464539/2021